The rise of metal radionuclides in medical imaging: Copper-64, zirconium-89 and yttrium-86

Future Medicinal Chemistry

Volumn 3, Issue 5, 2011, Pages 599-621

  Ikotun, Oluwatayo F ^a   Lapi, Suzanne E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7 TETRAZACYCLONONANE 1,4,7 TRIACETATE 8 AMINO OCTANOIC ACID BOMBESIN[7-14] CU 64; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETATE 8 AMINO OCTANOIC ACID BOMBESIN[7-14] CU 64; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GLUTAMYL [GLUTAMYL (CYCLO ARGINYLGLYCYLASPARTYLPHENYLALANYLVALINE) 2] 2 CU 64; 4,11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE 8 AMINO OCTANOIC ACID BOMBESIN[7-14] AMIDE CU 64; ARGINYLGLYCYLASPARTIC ACID CU 64; BOMBESIN DERIVATIVE; CAPROMAB PENDETIDE IN 111; COPPER 64; CYCLO ARGINYLGLYCYLASPARTYLPHENYLALANYLVALINE CU 64; CYCLOHEXYLDIETHYLENETRIAMINE PENTETATE OCTREOTIDE Y 86; DEFEROXAMINE; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; EDETIC ACID; GLYOXAL, BIS(THIOSEMICARBAZONATO) CU 64; IBRITUMOMAB TIUXETAN; OCTREOTIDE; PENTETIC ACID; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TOSITUMOMAB I 131; TRIENTINE; TRIENTINE OCTREOTIDE CU 64; TRIENTINE TYROSINE 3 OCTREOTATE CU 64; TYROSINE 3 OCTREOTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 86; ZIRCONIUM 89; ZIRCONIUM DERIVATIVE;

ALZHEIMER DISEASE; ANTIBODY LABELING; BINDING AFFINITY; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOID; CELL HYPOXIA; CHELATION; COLON CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CYCLOTRON; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG ISOLATION; DRUG PENETRATION; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG STABILITY; DRUG TISSUE LEVEL; DRUG UPTAKE; HEAD AND NECK CARCINOMA; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MOLECULAR IMAGING; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIOISOTOPE DECAY; RADIOISOTOPE DISTRIBUTION; RETICULOENDOTHELIAL SYSTEM; REVIEW; SQUAMOUS CELL CARCINOMA;

ANIMALS; COPPER RADIOISOTOPES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; YTTRIUM RADIOISOTOPES; ZIRCONIUM;

EID: 79955628977     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.11.14     Document Type: Review

References (129)

1. Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol. Imaging 9(1), 1-20 (2010).
2. Meijs WE, Herscheid JDM, Haisma HJ, Wijbrandts F, van Langevelde F, van Leuffen PJ. Production of highly pure no-carrier added 89Zr for the labeling of antibodies and a positron emitter. Appl. Radiat. Isot. 45, 1143-1147 (1994).
3. Dejesus OT, Nickles RJ. Production and purification of Zr-89, a potential pet antibody label. Appl. Radiat. Isot. 41(8), 789-790 (1990). (Pubitemid 20290490)
4. Avila-Rodriguez MA, Nye JA, Nickles RJ. Production and separation of noncarrier-added 86Y from enriched 86Sr targets. Appl. Radiat. Isot. 66(1), 9-13 (2008). (Pubitemid 350087675)
5. Reischl G, Rosch F, Machulla HJ. Electrochemical separation and purification of yttrium-86. Radiochimica Acta 90(4), 225-228 (2002).
6. Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol. 386, 237-261 (2004). (Pubitemid 38657596)
7. McCarthy DW, Shefer RE, Klinkowstein RE et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl. Med. Biol. 24(1), 35-43 (1997). (Pubitemid 27145595)
8. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev. 110(5), 2858-2902 (2010).
9. Pal S, Chattopadhyay S, Das MK, Sudersanan M. Production and separation of no-carrier-added radioactive tracers of yttrium, strontium and rubidium from heavy-ion irradiated germanium target: applicability to the standardization of a separation technique for production of positron-emitting radionuclide Y-86. Appl. Radiat. Isot. 64(12), 1521-1527 (2006). (Pubitemid 44647844)
10. Yoo J, Tang L, Perkins TA et al. Preparation of high specific activity Y-86 using a small biomedical cyclotron. Nucl. Med. Biol. 32(8), 891-897 (2005). (Pubitemid 41505323)
11. Zweit J, Downey S, Sharma HL. Production of no-carrier-added zirconium-89 for positron emission tomography. Appl. Radiat. Isot. 42(2), 199-201 (1991).
12. Hohn A, Zimmermann K, Schaub E, Hirzel W, Schubiger PA, Schibli R. Production and separation of nonstandard PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland. Q. J. Nucl. Med. Mol. Imaging 52(2), 145-150 (2008). (Pubitemid 351721934)
13. Link JM, Krohn KA, Eary JF. 89Zr for antibody labeling and positron tomography. J. Labeled Compd Radiopharm. 23, 1296-1297 (1986).
14. Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 44(8), 1271-1281 (2003). (Pubitemid 39662684)
15. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Des. 13(1), 3-16 (2007). (Pubitemid 46085298)
16. Zinn KR, Chaudhuri TR, Cheng TP, Morris JS, Meyer WA, Jr. Production of no-carrier-added 64Cu from zinc metal irradiated under boron shielding. Cancer 73(Suppl. 3), 774-778 (1994). (Pubitemid 24046630)
17. Szelecsenyi F, Blessing G, Qaim SM. Excitation function of proton induced nuclear reactions on enriched 61Ni and 64Ni: possibility of production of no-carrier-added 61Cu and 64Cu at a small cyclotron. Appl. Radiat. Isot. 44, 575-580 (1993). (Pubitemid 23069177)
18. Smith SV, Waters D, DiBartolo N. Carrier-free copper-64 isolated from Ga-67 waste for use in PET and therapy. J. Nucl. Med. 37(5), 894-894 (1996).
19. Qaim SM, Bisinger T, Hilgers K, Nayak D, Coenen HH. Positron emission intensities in decay of 64Cu, 76Br, and 124I. Radiochimica Acta 95, 67-73 (2007).
20. Firestone RB, Baglin CM, Chu SYF. In: Table of Isotopes, Volumes 1-2. Shirley VS (Ed.). John Wiley & Sons, Inc., NY, USA (1996).
21. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 36(7), 729-739 (2009).
22. Kandil SA, Scholten B, Saleh AM, Youssef SM, Qaim SM, Coenen HH. A comparative study on the separation of radiozirconium via ion-exchange and solvent extraction techniques, with particular reference to the production of 88Zr and 89Zr in proton induced reactions on yttrium. J. Radioanal. Nucl. Chem. 274, 45-52 (2007). (Pubitemid 47313147)
23. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem. 20(5), 825-841 (2009).
24. Perk LR, Visser OJ, Stigter-van Walsum M et al. Preparation and evaluation of (89) Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 33(11), 1337-1345 (2006). (Pubitemid 44630790)
25. Welch MJ, Laforest R, Lewis JS. Production of nonstandard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides. Ernst Schering Res. Found. Workshop (62), 159-181 (2007).
26. Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem. 148(1), 249-253 (1985). (Pubitemid 15031793)
27. Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res. 42(7), 832-841 (2009).
28. Hoffman TJ, Smith CJ. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl. Med. Biol. 36(6), 579-585 (2009).
29. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother. Radiopharm. 24(4), 379-393 (2009).
30. Tatum JL, Kelloff GJ, Gillies RJ et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 82(10), 699-757 (2006). (Pubitemid 44832019)
31. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 49(7), 1177-1182 (2008). (Pubitemid 351948028)
32. Dehdashti F, Mintun MA, Lewis JS et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur. J. Nucl. Med. Mol. Imaging 30(6), 844-850 (2003). (Pubitemid 36734203)
33. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 55(5), 1233-1238 (2003). (Pubitemid 36338289)
34. Lewis JS, Connett JM, Garbow JR et al. Copper-64-pyruvaldehyde-bis(N(4)- methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging. Cancer Res. 62(2), 445-449 (2002). (Pubitemid 34106417)
35. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J. Nucl. Med. 49(Suppl. 2), 129S-148S (2008). (Pubitemid 351948041)
36. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. (43), 4893-4902 (2007). (Pubitemid 350015414)
37. Lapi SE, Voller TF, Welch MJ. Positron emission tomography imaging of hypoxia. PET Clin. 4(1), 39-47 (2009).
38. Lewis J, Laforest R, Buettner T et al. Copper-64-diacetyl-bis(N4- methylthiosemicarbazone): an agent for radiotherapy. Proc. Natl Acad. Sci. USA 98(3), 1206-1211 (2001).
39. Fodero-Tavoletti MT, Villemagne VL, Paterson BM et al. Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer?s disease. J. Alzheimers Dis. 20(1), 49-55 (2010).
40. Lim S, Paterson BM, Fodero-Tavoletti MT et al. A copper radiopharmaceutical for diagnostic imaging of Alzheimer?s disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-b plaques. Chem. Commun. (Camb.) 46(30), 5437-5439 (2010).
41. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J. Nucl. Med. 36(10), 1825-1835 (1995).
42. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12(4), 450-482 (1991).
43. Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64-octreotide conjugates. J. Nucl. Med. 36(12), 2315-2325 (1995).
44. Dehdashti F, Anderson CJ, Trask DD et al. Initial results with PET imaging using Cu-64-labeled TETA-octreotide in patients with carinoid tumor. J. Nucl. Med. 38, 103P (1997).
45. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four 64Cu-labeled somatostatin analogs in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J. Med. Chem. 42(8), 1341-1347 (1999). (Pubitemid 29200869)
46. Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a novel CHX-A derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A-octreotide. J. Med. Chem. 49(14), 4297-4304 (2006). (Pubitemid 44036673)
47. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol. 155(6), 2067-2076 (1999).
48. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 59(5), 1152-1159 (1999). (Pubitemid 29135980)
49. Scheffel U, Pomper MG. PET imaging of GRP receptor expression in prostate cancer. J. Nucl. Med. 45(8), 1277-1278 (2004). (Pubitemid 47618521)
50. Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[d-TYR(6), b-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin. Cancer Res. 8(4), 1139-1146 (2002). (Pubitemid 35177367)
51. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res. Treat. 101(2), 175-183 (2007). (Pubitemid 46115423)
52. Rogers BE, Bigott HM, McCarthy DW et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analog. Bioconjug. Chem. 14(4), 756-763 (2003). (Pubitemid 36875435)
53. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogs containing different amino acid linker moieties. Bioconjug. Chem. 18(4), 1110-1117 (2007). (Pubitemid 47122631)
54. Yang YS, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl. Med. Biol. 33(3), 371-380 (2006).
55. Chen X, Park R, Hou Y et al. MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med. 45(8), 1390-1397 (2004). (Pubitemid 47618540)
56. Prasanphanich AF, Nanda PK, Rold TL et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc. Natl Acad. Sci. USA 104(30), 12462-12467 (2007). (Pubitemid 47206160)
57. Garrison JC, Rold TL, Sieckman GL et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J. Nucl. Med. 48(8), 1327-1337 (2007). (Pubitemid 47242799)
58. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol. Oncol. Clin. North Am. 18(5), 991-1006 (2004). (Pubitemid 39335755)
59. Tucker GC. av integrin inhibitors and cancer therapy. Curr. Opin. Investig. Drugs 4(6), 722-731 (2003).
60. Sprague JE, Kitaura H, Zou W et al. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J. Nucl. Med. 48(2), 311-318 (2007). (Pubitemid 47555359)
61. Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin avb3. Important Adv. Oncol. 69-87 (1996).
62. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697-715 (1996). (Pubitemid 26422728)
63. Wei L, Ye Y, Wadas TJ et al. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl. Med. Biol. 36(3), 277-285 (2009).
64. Chen X, Liu S, Hou Y et al. MicroPET imaging of breast cancer av-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol. Imaging Biol. 6(5), 350-359 (2004). (Pubitemid 39243068)
65. Wu Y, Zhang X, Xiong Z et al. MicroPET imaging of glioma integrin {a}v{b}3 expression using (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med. 46(10), 1707-1718 (2005). (Pubitemid 46211595)
66. Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ. Targeting the avb3 integrin for small-animal PET/CT of osteolytic bone metastases. J. Nucl. Med. 50(11), 1873-1880 (2009).
67. Gao L, Deng H, Zhao H et al. HTLV-1 tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 106(13), 4294-4302 (2005). (Pubitemid 41775939)
68. Siegrist W, Solca F, Stutz S et al. Characterization of receptors for a-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 49(22), 6352-6358 (1989). (Pubitemid 20000936)
69. Tatro JB, Wen Z, Entwistle ML et al. Interaction of an a-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res. 52(9), 2545-2548 (1992).
70. Jiang J, Sharma SD, Fink JL, Hadley ME, Hruby VJ. Melanotropic peptide receptors: membrane markers of human melanoma cells. Exp. Dermatol. 5(6), 325-333 (1996). (Pubitemid 27060540)
71. Tatro JB, Atkins M, Mier JW et al. Melanotropin receptors demonstrated in situ in human melanoma. J. Clin. Invest. 85(6), 1825-1832 (1990). (Pubitemid 20192956)
72. Wei L, Zhang X, Gallazzi F et al. Melanoma imaging using (111)In-, (86)Y- and (68) Ga-labeled CHX-A-Re(Arg-11)CCMSH. Nucl. Med. Biol. 36(4), 345-354 (2009).
73. Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ. Evidence for a-melanocyte-stimulating hormone (a-MSH) receptors on human malignant melanoma cells. Int. J. Cancer 41(2), 248-255 (1988). (Pubitemid 18061152)
74. Cornish J, Callon KE, Mountjoy KG et al. a-melanocyte-stimulating hormone is a novel regulator of bone. Am. J. Physiol. Endocrinol. Metab. 284(6), E1181-E1190 (2003). (Pubitemid 36617466)
75. Sawyer TK, Castrucci AM, Staples DJ et al. Structure-activity relationships of [Nle4, d-Phe7]a-MSH. Discovery of a tripeptidyl agonist exhibiting sustained bioactivity. Ann. NY Acad. Sci. 680, 597-599 (1993). (Pubitemid 23201080)
76. McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analog of a-MSH. J. Med. Chem. 48(8), 2985-2992 (2005). (Pubitemid 40548110)
77. Wei L, Butcher C, Miao Y et al. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized a-MSH peptide analog using a cross-bridged cyclam chelator. J. Nucl. Med. 48(1), 64-72 (2007). (Pubitemid 47555377)
78. Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr. Opin. Drug Discov. Devel. 10(2), 167-175 (2007). (Pubitemid 46438646)
79. Cheng Z, De Jesus OP, Kramer DJ et al. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol. Imaging Biol. 12(3), 316-324 (2009).
80. Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Small-animal PET imaging of human epidermal growth factor receptor-positive tumor with a 64Cu labeled affibody protein. Bioconjug. Chem. 21(5), 947-954 (2010).
81. Forster GJ, Engelbach MJ, Brockmann JJ et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor-positive tumours: comparison of (86)Y-DOTATOC and (111) In-DTPA-octreotide. Eur. J. Nucl. Med. 28(12), 1743-1750 (2001).
82. Jamar F, Barone R, Mathieu I et al. 86Y-DOTA0)-d-Phe1-Tyr3-octreotide (SMT487) - a Phase I clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imaging 30(4), 510-518 (2003). (Pubitemid 36559829)
83. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol. 9(6), 423-430 (2008).
84. van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother. Radiopharm. 25(4), 375-385 (2010).
85. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 14(3), 191-197 (2008).
86. Williams LE, Wu AM, Yazaki PJ et al. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother. Radiopharm. 16(1), 25-35 (2001). (Pubitemid 32231714)
87. McCabe KE, Wu AM. Positive progress in immunoPET - not just a coincidence. Cancer Biother. Radiopharm. 25(3), 253-261 (2010).
88. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2(1), 52-62 (2003). (Pubitemid 37361624)
89. Reardan DT, Meares CF, Goodwin DA et al. Antibodies against metal chelates. Nature 316(6025), 265-268 (1985). (Pubitemid 15073694)
90. Goodwin DA, Meares CF, David GF et al. Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Int. J. Rad. Appl. Instrum. B 13(4), 383-391 (1986). (Pubitemid 16006450)
91. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J. Nucl. Med. 28(8), 1294-1302 (1987). (Pubitemid 17156417)
92. Sharkey RM, Karacay H, Cardillo TM et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin. Cancer Res. 11(19), 7109s-7121s (2005). (Pubitemid 41428712)
93. Martensson L, Nilsson R, Ohlsson T, Sjogren HO, Strand SE, Tennvall J. Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy. Clin. Cancer Res. 13(18), 5572s-5576s (2007). (Pubitemid 47510389)
94. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur. J. Nucl. Med. Mol. Imaging 34(6), 850-858 (2007). (Pubitemid 46798960)
95. Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of Cu-64-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother. Radiopharm. 23(2), 158-171 (2008). (Pubitemid 351630188)
96. Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J. Nucl. Med. 50(7), 1116-1123 (2009).
97. Elsasser-Beile U, Reischl G, Wiehr S et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J. Nucl. Med. 50(4), 606-611 (2009).
98. Niu G, Li ZB, Cao QZ, Chen XY. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with Cu-64-DOTA- trastuzumab. Eur. J. Nucl. Med. Mol. Imaging 36(9), 1510-1519 (2009).
99. Wu AM, Yazaki PJ, Tsai S et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl Acad. Sci. USA 97(15), 8495-8500 (2000). (Pubitemid 30639701)
100. Li L, Bading J, Yazaki PJ et al. A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug. Chem. 19(1), 89-96 (2008). (Pubitemid 351213839)
101. Philpott GW, Schwarz SW, Anderson CJ et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J. Nucl. Med. 36(10), 1818-1824 (1995).
102. Lovqvist A, Humm JL, Sheikh A et al. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels. J. Nucl. Med. 42(8), 1281-1287 (2001). (Pubitemid 32717850)
103. Nayak TK, Regino CA, Wong KJ et al. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A-DTPA-cetuximab. Eur. J. Nucl. Med. Mol. Imaging 37(7), 1368-1376 (2010).
104. Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. J. Nucl. Med. 51(6), 942-950 (2010).
105. Schneider DW, Heitner T, Alicke B et al. In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J. Nucl. Med. 50(3), 435-443 (2009).
106. Aerts HJ, Dubois L, Perk L et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med. 50(1), 123-131 (2009).
107. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med. 51(8), 1293-1300 (2010).
108. Nagengast WB, de Vries EG, Hospers GA et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 48(8), 1313-1319 (2007). (Pubitemid 47242797)
109. Borjesson PK, Jauw YW, Boellaard R et al. Performance of immuno-positron emission tomography with zirconium-89- labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res. 12(7 Pt. 1), 2133-2140 (2006).
110. Borjesson PK, Jauw YW, de Bree R et al. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J. Nucl. Med. 50(11), 1828-1836 (2009).
111. Dijkers EC, Oude Munnink TH, Kosterink JG et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87(5), 586-592 (2010).
112. Glaus C, Rossin R, Welch MJ, Bao G. In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug. Chem. 21(4), 715-722 (2010).
113. Minchin RF, Martin DJ. Nanoparticles for molecular imaging - an overview. Endocrinology 151(2), 474-481 (2010).
114. Chen K, Li ZB, Wang H, Cai W, Chen X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur. J. Nucl. Med. Mol. Imaging 35(12), 2235-2244 (2008).
115. Michalet X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307(5709), 538-544 (2005). (Pubitemid 40165671)
116. Bruchez M Jr., Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science 281(5385), 2013-2016 (1998). (Pubitemid 28475485)
117. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 281(5385), 2016-2018 (1998). (Pubitemid 28475486)
118. Cai W, Chen K, Li ZB, Gambhir SS, Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med. 48(11), 1862-1870 (2007). (Pubitemid 350099333)
119. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. Nat. Mater. 4(6), 435-446 (2005). (Pubitemid 40774047)
120. Vuu K, Xie J, McDonald MA et al. Gadolinium-rhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. Bioconjug. Chem. 16(4), 995-999 (2005). (Pubitemid 41026185)
121. van Tilborg GA, Mulder WJ, Deckers N et al. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug. Chem. 17(3), 741-749 (2006). (Pubitemid 43794385)
122. Rieter WJ, Kim JS, Taylor KM, An H, Lin W, Tarrant T. Hybrid silica nanoparticles for multimodal imaging. Angew. Chem. Int. Ed. Engl. 46(20), 3680-3682 (2007). (Pubitemid 46981247)
123. Kim JS, Rieter WJ, Taylor KM, An H, Lin W. Self-assembled hybrid nanoparticles for cancer-specific multimodal imaging. J. Am. Chem. Soc. 129(29), 8962-8963 (2007). (Pubitemid 47171835)
124. Islam T, Josephson L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark. 5(2), 99-107 (2009).
125. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug. Chem. 13(3), 554-560 (2002). (Pubitemid 34527517)
126. Jennings LE, Long NJ. ?Two is better than one? - probes for dual-modality molecular imaging. Chem. Commun. (Camb.) (24), 3511-3524 (2009).
127. Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117(3), 379-387 (2008).
128. Holland JP, Caldas-Lopes E, Divilov V et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One 5(1), e8859 (2010).
129. Dijkers EC, Kosterink JG, Rademaker AP et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/ neu immunoPET imaging. J. Nucl. Med. 50(6), 974-981 (2009).